Can anything threaten Novo and Lilly’s obesity market dominance?

Five GLP-1 products will collectively bring in $470 billion by 2030, and the market leaders are working to hold back competition.

How a scrapped Pfizer drug became a winner for SpringWorks

SpringWorks Therapeutics and the Children’s Tumor Foundation salvaged a shelved asset for neurofibromatosis and got it over the regulatory finish line.

A big moment is coming for psychedelics

Compass Pathways expects to publish the first phase 3 results from a large-scale, psilocybin drug trial by the end of this quarter.

Novartis scores NFL deal to tackle health outcomes

The non-traditional marketing approach comes amid a potential crackdown on TV drug ads.